Breaking AI & Tech News Analyzed

Game 7 Recap: Spurs Edge Thunder 111‑103 The Western Conference finals culminated in a dramatic Game 7 where the San Antonio Spurs survived a late foul on Victor Wembanyama and a decisive block by Luke Kornet to clinch a 111‑103 victory over the Oklahoma City Thunder. The win sends the Spurs to the NBA Finals for the first time since 2024. Key Moments That Shifted Momentum Wembanyama’s fifth foul in the fourth quarter forced him to sit, removing the Spurs’ primary interior presence. Luke Kornet’s chase‑down block on Isaiah Hartenstein sparked a quick Spurs run, extending the lead to eight points. Shai Gilgeous‑Alexander scored 35 of the Thunder’s 31 points from starters, but the bench contributed only 14 fourth‑quarter points. The Spurs’ bench outscored the Thunder’s starters for most of the series, a trend that proved decisive in Game 7. Statistical Snapshot of the Deciding Game Final Score: Spurs 111, Thunder 103 Victor Wembanyama: 12 points, 7 rebounds, fouled out in the fourth quarter. Shai Gilgeous‑Alexander: 35 points (team‑high), 5 assists. Luke Kornet: 8 points, 4 rebounds, 1 block (crucial chase‑down). Spurs Bench: 38 points combined, highlighted by Keldon Johnson (two threes) and Julian Champagnie (6‑of‑10 shooting). Thunder Bench: 14 fourth‑quarter points, limited impact overall. What the Upset Means for the NBA Landscape The Thunder’s early‑season dominance (24‑1 start) made them favorites, but the series exposed a reliance on Gilgeous‑Alexander and a bench that could be neutralized when Wembanyama rested. The Spurs demonstrated depth and resilience, reinforcing the notion that playoff success hinges on contributions beyond star players. Fan sentiment toward the Thunder’s “unpopular” style of drawing fouls may intensify, while the Spurs’ narrative shifts from underdog to legitimate championship contender. Looking Ahead: Spurs vs Knicks in the Finals Next up, the Spurs will face a rested New York Knicks team that entered the playoffs on an 11‑game winning streak. The Knicks’ balanced roster and recent momentum pose a fresh challenge, but the Spurs’ experience in Game 7 and their bench firepower give them a credible shot at the title. Meanwhile, the Thunder are expected to regroup, address depth concerns, and return stronger next season.

High‑resolution satellite imagery released on 25 February 2026 reveals that the Sheikh Mohammed cemetery in Khan Younis has been erased and turned into an Israeli military outpost, while entire neighbourhoods across southern Gaza have been reduced to rubble. The visual evidence, highlighted by Al Jazeera, illustrates a broader pattern of territorial expansion and cultural erasure. Satellite proof of Gaza’s reshaped landscape The updated Google‑Earth layers show the former cemetery, residential blocks in Rafah, the Swedish‑built coastal village, and the Hamad City housing project all replaced by fortified positions, tents and debris. The images capture the disappearance of streets, the flattening of the 752‑unit Tal as‑Sultan housing project, and the conversion of the Rafah border crossing into a heavily fortified military zone. Human‑cost statistics from the ground and from monitors 73,000 Palestinians killed since the conflict escalated. 94 % of Gaza’s cemeteries fully or partially destroyed (Euro‑Med Human Rights Monitor). 97 % of schools damaged or destroyed, leaving 658,000 children without formal education. 1.9 million of 2.3 million residents internally displaced. 60 % of the population has lost their homes completely. Only 5 % of Gaza’s agricultural land remains usable (FAO). Israeli forces now control roughly 70 % of the Strip, up from 60 % earlier this year (leaked video of Benjamin Netanyahu). Implications for the humanitarian and geopolitical landscape The systematic demolition of cemeteries, schools and farms not only erases physical landmarks but also attacks collective memory and food security. With agricultural output slashed to under five percent, experts warn Gaza is on the brink of famine. The loss of educational infrastructure threatens a generation of Palestinians, while the expanding occupation deepens violations of the October cease‑fire and raises the risk of a protracted, “permanent” status quo, as warned by UN envoy Nickolay Mladenov. What lies ahead: risks and possible international responses If the current trajectory continues, Gaza could face a full‑scale famine within months, prompting urgent calls for a new cease‑fire and humanitarian corridors. International pressure may increase as documentation of cultural erasure and mass displacement fuels advocacy campaigns. However, without a clear shift in Israeli policy or renewed diplomatic engagement, the occupation could solidify, making reconstruction and return of displaced families increasingly unlikely.

Iga Swiatek's bid for a fifth Roland Garros title ended abruptly on her 25th birthday, as she fell 7‑5, 6‑1 to Ukraine's 15th‑seed Marta Kostyuk in the round of 16. Swiatek’s Fifth Title Quest Ends in the Round of 16 The former champion entered Paris as the clear favorite, but Kostyuk's aggressive baseline play and mental composure proved decisive. After trading early breaks, Kostyuk seized a crucial 11th‑game break to close the first set, then dominated the second with a 6‑1 surge. Numbers That Reveal the Scale of the Upset Scoreline: 7‑5, 6‑1 in favor of Kostyuk Seedings: Swiatek (4) vs. Kostyuk (15) Kostyuk’s 2026 clay record: 15‑0 entering the match Swiatek’s birthday: May 31, 2001 (turned 25) Other recent upsets: Jannik Sinner, Novak Djokovic, Coco Gauff, and China’s Wang Xinyu all exited within three days Implications for the Women’s Grand Slam Landscape Swiatek’s departure elevates world No.1 Aryna Sabalenka to the clear favorite for her first French Open crown. It also signals a shift toward greater depth on the WTA tour, where lower‑seeded players like Kostyuk and veteran Sorana Cirstea—who reached her first Roland Garros quarter‑final in 17 years—are capable of toppling the elite. What to Expect in the Remaining French Open Rounds Kostyuk will face either 7th‑seed Elina Svitolina or 11th‑seed Belinda Bencic in the quarter‑finals, while Sabalenka is expected to navigate a draw that now lacks its former dominant force. The tournament is likely to produce at least one more surprise, as the momentum gained by emerging clay‑court specialists continues to challenge the traditional hierarchy.

The LeadA daily pill has shown remarkable results in doubling survival time for patients with pancreatic cancer, the world's deadliest form of the disease. According to clinical trial results presented at the American Society of Clinical Oncology's annual meeting, this breakthrough treatment represents a potential revolution in how we approach a cancer that has seen limited progress for decades.The Breakthrough Drug: DaraxonrasibThe drug in question, daraxonrasib, works by targeting a protein called Kras that fuels nearly all pancreatic cancers. This mechanism represents a significant advancement in treatment strategy, as Kras has been notoriously difficult to target effectively. The drug functions as a Ras(On) multi-selective inhibitor, capable of turning off the Kras protein to stop cancer growth regardless of which variant is present.Impressive Trial ResultsIn the clinical trial involving 500 patients with advanced pancreatic cancer, the results were striking. Those who took daraxonrasib lived an average of 13.2 months, compared to just 6.6 to 6.7 months for patients who received chemotherapy. This represents a near doubling of survival time, with the added benefit of fewer side effects compared to traditional chemotherapy treatments.Industry Impact and Expert ReactionsThe findings have been hailed as a "gamechanger" and "grand slam" by experts in the field. Dr. Rachna Shroff, chief of oncology at the University of Arizona Cancer Center, described the results as "landscape-changing" and "unprecedented survival." When she first read the trial results, conducted by researchers at the Dana-Farber Cancer Institute in Boston, she wept, noting the profound impact this could have on patients after 16 years of treating pancreatic cancer.Dr. Julie Gralow, Asco's chief medical officer, echoed these sentiments, calling the study a "home run" and suggesting it was actually a "grand slam" in terms of its significance.The Ras RevolutionOver 90% of patients with the most common form of pancreatic cancer, pancreatic ductal adenocarcinoma (mPDAC), have a mutation in the Kras gene. This discovery has long been considered the "holy grail" in cancer research, particularly for pancreatic cancer where the mutation is nearly ubiquitous and an early driver of cancer growth.Paula Hanford, chief executive of UK-based Pancreatic Cancer Action, called this one of the most significant developments in treatment she had ever seen. Similarly, Anna Jewell, director of services, research and innovation at Pancreatic Cancer UK, described the results as "exciting," noting that the drug gives patients "months more precious time with their loved ones."Future Outlook and ApplicationsThe success of daraxonrasib opens doors for similar treatments targeting Ras genes in other cancers. Experts at the conference noted that because Ras genes fuel various types of cancer, there is hope for breakthroughs in treating lung and colon cancers as well, with similar drugs already in development for these conditions.However, challenges remain in ensuring these promising treatments become widely available to patients. As Jewell pointed out, tragically half of all people with pancreatic cancer die within just three months of diagnosis, making the rapid implementation of such treatments crucial.

Iga Swiatek's Unhappy Birthday at French Open Iga Swiatek's 25th birthday celebrations turned sour at the French Open on Sunday as the former champion lost 7-5, 6-1 in the fourth round to the Ukrainian 15th seed Marta Kostyuk, her challenge for a fifth title ending just when she had looked to be rediscovering her rhythm. The Match Turning Point There was little to separate the duo in the early exchanges as they twice traded breaks, before Kostyuk came up with a tight hold in the 11th game and raised her level at the end to claim the opening set with a backhand crosscourt winner. Kostyuk's Historic Win It was the first time that Kostyuk had taken a set off the third-seeded Pole after three straight-set defeats in their previous meetings, and she sensed a big upset when she went ahead 3-1 in the next set after a battling effort. The Impact on Swiatek's Title Hopes The Rouen and Madrid champion held her nerve from there to take her record on clay this season to 15-0, and book a meeting with the seventh-seeded Ukrainian Elina Svitolina or the 11th-seeded Swiss Belinda Bencic in the next round at Roland Garros. What's Next Tumaini Carayol’s report to follow

The Lead: Liverpool at a CrossroadsAs Liverpool prepares for life after Arne Slot, the club faces significant challenges that will define their immediate future. The Dutchman's tenure ended without the dominance expected, leaving a squad in need of strategic overhaul both on and off the pitch. The new manager inherits a team that must rediscover its identity while addressing key personnel departures and tactical shortcomings.Style Evolution: From Heavy Metal to Soft RockPerhaps Mohamed Salah's style of communication wasn't the slickest, but he was correct that Liverpool need to redefine the style of football they play. Everything on the pitch last season under Arne Slot felt very placid as Liverpool failed to dominate opponents and were often found overrun. The new head coach will want to demonstrate his plans and implement an attacking style to best use what is available to him. Anfield does not want to witness back-foot football, fans want to see a swagger to those in red. Supporters and Slot suffered from a disconnect in the final months. The Dutchman was hindered by not possessing the vivacious personality of Jürgen Klopp nor the results in the end, and the aforementioned tedious style. The successor will want to put fans at the forefront and build a strong bond between stands and dugout, built on a platform of attractive play.Investment Analysis: Underperforming Key SigningsAfter spending heavily last summer trying to build a squad capable of dominating the Premier League for years to come, it was difficult to pick out someone who thrived. Hugo Ekitiké was the best of the new arrivals but record signings Florian Wirtz and Alexander Isak barely made the season's footnotes. Isak could at least attribute his struggles to fitness and injury problems, including a leg fracture, but the German's first taste of English football was a sour one. He never looked comfortable as a No 10, physically finding it tough going as speed on the ball and strength in battle were lacking. Getting the best out of a clearly talented player must be a priority, because Wirtz has the capabilities to open defences and help Liverpool control games but needs a confidence boost and an arm around the shoulder.Structural Impact: Midfield Deficiencies and Leadership VacuumWirtz is part of a wider midfield issue that lacks physicality and an obvious No 6. Ryan Gravenberch was elected as the man for the role by Slot, which worked well when the possession stats were in Liverpool's favour but finding someone who can break things up effectively is advisable. Every other team have someone who can break up play but Liverpool lack someone in that role. Not since Georginio Wijnaldum or Fabinho have the club possessed someone capable of overwhelming opponents with their physical attributes and in an evolving sport, this oversight must end. Dominik Szoboszlai being moved around the pitch was unhelpful because he can be one of the best central midfielders in the world but needs a defined position to make his own.The players departing Anfield are weighed down with individual and team trinkets, thanks to the success they have enjoyed with Liverpool. Arguably, the influence of Salah and Andy Robertson on the pitch waned in their final season with the club but their experience and winning mentality will be a huge loss to the dressing room and training ground. Ibrahima Konaté is another exiting, providing a recruitment headache the club were not fully anticipating. It does beg the question if it is the right time to allow Alisson Becker, who has suffered from injury problems in recent times, to be sold and allow a new generation to start afresh, with Virgil van Dijk leading the transition. There are plenty of potential internal candidates who can take on greater responsibility but it may require a change in transfer strategy to acquire players in their late-20s with Champions League experience to help give the right balance.Defensive Rebuild: Addressing Key DeparturesKonaté's contract expiration will be softened by Jérémy Jacquet's impending arrival but further investment is required. Van Dijk's longevity is unknown so finding a partnership for the long term will be critical; a more rugged centre-back like Nottingham Forest's Murillo could be an ideal choice to offer balance and greater aggression. Competition for Milos Kerkez will be important, but if Andoni Iraola does take the job the reunion could get the best out of the Hungarian and get him to flourish after a mixed first year on Merseyside. On the opposite side, continuity would help everyone because Slot was forced to trying numerous people in the role, many out of position. Ideally, Conor Bradley or Jeremie Frimpong can make it their own, having struggled to replace Trent Alexander-Arnold, although both have suffered with injury problems. If they can stay fit, they both possess the quality to be a solution, especially if clever coaching can embrace their attacking prowess and incorporate more defensive discipline.Future Outlook: Rebuilding the AttackSlot insisted that new wingers would change the dynamic next season but he will not be the one to benefit. Salah is off, Federico Chiesa cannot carry on as a bit-part, so will almost certainly leave too, freeing up some space on the flanks. Rio Ngumoha offered brief teenage glimpses of excitement as someone with the pace and trickery to get past full-backs. Frimpong, brought in as a right-back, was more often found on the wing because he possessed the speed Slot desired in those areas, while also offering a further indication that the transfer dealings left a lot to be desired. They did not replace the maverick tendencies of Luis Díaz and Cody Gakpo has never looked a natural winger. Targeting new wide men will be imperative. RB Leipzig's Yan Diomande, Brighton's Yankuba Minteh or Athletic Club's Neco Williams would be ideal candidates to bring thrust to a side lacking dynamism and get supporters off their seats.

The Connection to Nature As a recent study revealed almost half of UK adults now spend less than three hours a week in natural settings such as gardens, parks, fields or woods, we asked readers to tell us about what being outside means to them. Personal Stories of Healing The replies – heartfelt and passionate – came flooding in, with some admitting they just did not have the words to say how important it is. “It’s my happy place, my therapy and a reason to slow down and pause during my busy week,” wrote Hannah Powell from Perrywood garden centres. “I HAVE to look at plants every day. I notice every change in the garden. I sit facing the garden for my breakfast. I look out for nature on the way to work (recently seeing a little owl, red kites, foxes, hares, and more). It helped me get better when I had burnout and FND in London. I wouldn’t (couldn’t) be without it.” The Science Behind Nature's Benefits David Lynch esaid about his love of being outside. “Anxiety levels drop, all worldly concerns are put in perspective and [I] feel younger.” He agreed with others that there was plenty of recent science explaining the health benefits, but added: “I also read about ancient wisdom of Buddhism, which advocates solitary time in nature. All sources uphold the truth that better connection with nature brings better self-awareness and increased sensitivity to the needs of our ecosystem, plus better connection with each other.” The Impact on Mental Health Isabel Romaniw, who is working towards becoming a forest bathing guide, wrote passionately about the basic human need to be outside and to connect with nature. “We are animal, a simultaneously ordinary and yet utterly remarkable part of the great, miraculous tapestry of life on Earth. We have done much to shape our world and influence the fates of almost all other species we share our world with, but we must remember that we are but a tiny chapter, perhaps a footnote, in the ongoing story of the universe, in order to start to heal the damage and repair our relationships with ourselves, with each other, with our other-than-human kin, and with our one precious home.” For Romaniw, as for many others, our disconnection with nature is closely linked to “the worsening physical, mental and spiritual health crises that seem to be going on”. Cherished Memories of Nature Many of you had wonderful memories of times outside. “I was a sickly, pasty, shy, anxious kid,” wrote Mat Jordan. “In the early 70s my parents couldn’t afford to take us to the seaside one year so we went camping in the Peak District instead. It was a revelation. I absolutely loved it. The landscape and dry-stone walls of the white peak are still a favourite, although I spent some years in my 20s living in the Lake District too. One of my favourite memories is driving out of Sheffield into the Peaks with my then baby son to get him to fall asleep and still being awe-struck at the beauty on our doorstep.”

Day eight of the 2026 French Open at Roland‑Garros kicked off with a marquee clash between four‑time champion Iga Swiatek and rising talent Marta Kostyuk, alongside a host of other high‑stakes matches that could reshape the second week.Swiatek Takes on Kostyuk in a Potential ClassicThe opening encounter pits the defending champion, seeded #1, against the Ukrainian prodigy, seeded #12. Both players have displayed a blend of power and finesse throughout the tournament, setting the stage for a match that could define the women's title race.Seedings and Rankings Highlight the StakesIga Swiatek – World No. 1, French Open champion 2022‑2025.Marta Kostyuk – World No. 12, semifinalist in 2025.Jil Teichmann vs Mirra Andreeva – both ranked inside the top 30.Andrey Rublev – former top‑5, seeking a deep run after early exits by Djokovic, Alcaraz and Sinner.Implications for the Women’s Draw and Emerging ContendersA Swiatek victory would reinforce her dominance and likely secure a top‑seeded path to the final. A Kostyuk upset could open the draw for players like Elina Svitolina and Belinda Bencic, who are already positioned as dark horses.What to Watch in the Remainder of Day EightHow qualifier Wang Xiyu adapts to the clay after a surprise run.The performance of Jodár against Pedro Carreño Busta (men’s match).Whether Andrey Rublev can capitalize on the absence of the “Big Three”.

The Lead: Unprecedented Cancer Treatment SuccessDoctors have hailed "unprecedented" trial results that show a triple-action cancer jab can eradicate entire tumours in patients. In an international trial spanning 11 countries, the injection was offered to patients whose cancer had spread or come back and whose disease had failed to respond to other treatments.The Breakthrough: Amivantamab's Triple-Action ApproachThe jab, called amivantamab, shrank the tumours of more than a third of patients, with dramatic changes seen within weeks. In 15 of them, doctors found the drug had melted away their tumours altogether.The smart jab targets cancer in three ways. It blocks both EGFR (epidermal growth factor receptor), a protein that helps tumours grow, and MET, a pathway that cancer cells often use to escape treatment. It also helps activate the immune system to attack the tumour.The Clinical Trial Data: Impressive Response RatesIn the trial, 102 patients with head and neck cancer, the world's sixth most common cancer, were given the jab. Tumours shrank or disappeared completely in 43 patients, including 28 whose tumours shrank significantly and 15 who saw them eradicated entirely.Patients receiving amivantamab lived for a median of 12.5 months overall after starting treatment, despite having a form of cancer with very poor outcomes, once standard treatments stop working.The Impact Analysis: New Hope for Treatment-Resistant CancersKevin Harrington, professor in biological cancer therapies at the Institute of Cancer Research, London (ICR), said: "These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy. This is a group of patients for whom treatment options are extremely limited, so seeing this level of benefit is very striking."Researchers also highlighted that the trial focused on people with head and neck cancers that did not include those with human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma. That is particularly significant, they said, since head and neck cancers not caused by HPV are usually harder to treat, making progress in this group hugely important.The Patient Experience: Transforming Quality of LifeOne of the first patients to benefit was Carl Walsh, 56, who was diagnosed with tongue cancer in May 2024 and joined the OrigAMI-4 trial at the Royal Marsden in July 2025. "I was initially treated with both chemotherapy and immunotherapy, which unfortunately were not successful," he said. "At that point, I was recommended for the OrigAMI-4 trial. I'm now on my 17th cycle of treatment and I'm very pleased with the progress so far."Unlike many cancer treatments, amivantamab is given as a tiny jab under the skin rather than via an intravenous drip, making treatment quicker and more convenient for patients and much easier to deliver in outpatient clinics.The Future Outlook: Expanding Treatment ApplicationsThe results will be presented on Sunday in Chicago at the world's largest cancer conference, the annual meeting of the American Society of Clinical Oncology (Asco).Amivantamab, developed by Johnson & Johnson, is now being evaluated in about 60 clinical trials, primarily for lung cancer, but also for colorectal, brain and gastric cancers.Prof Kristian Helin, the chief executive of the ICR, said: "This study demonstrates how the development of new treatments through rigorous cancer research may lead to meaningful advances, even for patients with very limited treatment options. Achieving this level of tumour response and encouraging survival outcomes in such a challenging-to-treat group represents a significant step forward."